aspirin has been researched along with gemcitabine in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Benekli, M; Buyukberber, S; Coskun, U; Kaya, AO; Ozdemir, M; Ozturk, B; Sahin, G; Tacoy, G; Topal, S; Yaman, E; Yildiz, R | 1 |
| He, SM; Huang, YJ; Leng, TD; Li, Y; Ou, YQ; Qiu, PX; Xie, J; Xu, D; Yan, GM; Zheng, XK; Zhu, Wb | 1 |
| Bartsch, DK; Buchholz, M; Fendrich, V; Fichtner-Feigl, S; Kesselring, R; Knoop, R; Plassmeier, L; Waldmann, J | 1 |
| Bauer, N; Bazhin, AV; Fan, P; Fortunato, F; Giese, NA; Gladkich, J; Gross, W; Hackert, T; Herr, I; Hinz, U; Liu, L; Ryschich, E; Strobel, O; Zhang, Y | 1 |
| Li, Y; Liao, Q; Liu, Q; Lu, Z; Niu, Z; Wang, M; Yao, L; Zhao, Y; Zong, Y | 1 |
| Amin, S; K Pandey, M; Karelia, DN; Kim, S; Lu, J; Plano, D; Sharma, AK | 1 |
1 review(s) available for aspirin and gemcitabine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
10 other study(ies) available for aspirin and gemcitabine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Gemcitabine-induced acute coronary syndrome: a case report.
Topics: Antimetabolites, Antineoplastic; Aspirin; Bundle-Branch Block; Clopidogrel; Coronary Artery Disease; Coronary Vasospasm; Deoxycytidine; Electrocardiography; Fatal Outcome; Female; Gemcitabine; Humans; Leiomyosarcoma; Lung Neoplasms; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine | 2009 |
Aspirin inhibits proliferation of gemcitabine-resistant human pancreatic cancer cells and augments gemcitabine-induced cytotoxicity.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Aspirin; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Deoxycytidine; Drug Synergism; Flow Cytometry; Gemcitabine; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2 | 2010 |
Aspirin prolongs survival and reduces the number of Foxp3+ regulatory T cells in a genetically engineered mouse model of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Aspirin; Carcinoma, Pancreatic Ductal; Cyclooxygenase Inhibitors; Deoxycytidine; Disease Models, Animal; Drug Therapy, Combination; Forkhead Transcription Factors; Gemcitabine; Mice; Mice, Transgenic; Pancreatic Neoplasms; T-Lymphocytes, Regulatory | 2013 |
Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Chick Embryo; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
Atorvastatin (Lipitor) attenuates the effects of aspirin on pancreatic cancerogenesis and the chemotherapeutic efficacy of gemcitabine on pancreatic cancer by promoting M2 polarized tumor associated macrophages.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antimetabolites, Antineoplastic; Aspirin; Atorvastatin; Cell Line; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Macrophages; Male; Mice; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Novel Seleno-Aspirinyl Compound AS-10 Induces Apoptosis, G1 Arrest of Pancreatic Ductal Adenocarcinoma Cells, Inhibits Their NF-κB Signaling, and Synergizes with Gemcitabine Cytotoxicity.
Topics: Acetylcysteine; Adenocarcinoma; Apoptosis; Aspirin; Carcinoma, Pancreatic Ductal; Caspases; Cell Line, Tumor; Cell Proliferation; Cytokines; Deoxycytidine; Enzyme Activation; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inflammation Mediators; NF-kappa B; Pancreatic Neoplasms; Signal Transduction; Transcriptome | 2021 |